Yahoo
BVB RON

Antibiotice S.A. (ATB.RO)

1.9100 -0.0060 (-0.31%)
At close: 5:50:22 PM GMT+2
Chart Range Bar
Loading chart for ATB.RO
  • Previous Close 1.9160
  • Open 1.9160
  • Bid 1.8980 x --
  • Ask 1.9100 x --
  • Day's Range 1.8960 - 1.9180
  • 52 Week Range 1.7520 - 2.5900
  • Volume 31,217
  • Avg. Volume 103,102
  • Market Cap (intraday) 1.282B
  • Beta (5Y Monthly) 0.22
  • PE Ratio (TTM) 191.00
  • EPS (TTM) 0.0100
  • Earnings Date --
  • Forward Dividend & Yield 0.04 (1.87%)
  • Ex-Dividend Date Oct 15, 2026
  • 1y Target Est --

Antibiotice S.A. produces and sells medicinal products in Romania and internationally. The company provides generic prescription medicines comprising anti-infectives, including drugs for the treatment of tuberculosis, as well as cardiovascular drugs, digestive tract and metabolism class, preparations for the treatment of gynecological diseases, and dermatological and central nervous system preparations; generic non-prescription medicines, including food supplements, cosmetics, and medical devices; active substances; biofertilizers; biocides for disinfecting surfaces and hands; and veterinary medicines. Its products are available in the form of sterile injectable powders, capsules, tablets, ointments, gels, creams, pessaries, and suppositories. It offers active pharmaceutical ingredients. The company exports its products to approximately 70 countries. Antibiotice S.A. was founded in 1955 and is headquartered in Iasi, Romania.

www.antibiotice.ro

1,354

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/3/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

ATB.RO
20.63%
MSCI WORLD (^990100-USD-STRD)
9.60%

1-Year Return

ATB.RO
21.75%
MSCI WORLD (^990100-USD-STRD)
10.48%

3-Year Return

ATB.RO
68.53%
MSCI WORLD (^990100-USD-STRD)
68.38%

5-Year Return

ATB.RO
262.55%
MSCI WORLD (^990100-USD-STRD)
51.15%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 136.53M
Earnings 12.56M
Profit Margin 9.20%

Q4

FY13

Q1

FY14

Q3

FY14

Q1

FY26

0
50M
100M
4.0%
6.0%
8.0%
10.0%
12.0%
14.0%

Analyst Insights

View More

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.32%

  • Return on Assets (ttm)

    1.11%

  • Return on Equity (ttm)

    0.87%

  • Revenue (ttm)

    616.58M

  • Net Income Avi to Common (ttm)

    8.13M

  • Diluted EPS (ttm)

    0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.08M

  • Total Debt/Equity (mrq)

    37.98%

  • Levered Free Cash Flow (ttm)

    -74.44M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: